RI2 Stock Overview A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Rigel Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Rigel Pharmaceuticals Historical stock prices Current Share Price US$15.00 52 Week High US$26.80 52 Week Low US$7.71 Beta 1.31 1 Month Change -21.47% 3 Month Change 10.29% 1 Year Change 24.79% 3 Year Change -23.92% 5 Year Change -44.03% Change since IPO -81.25%
Recent News & Updates
Rigel Pharmaceuticals, Inc. Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition Dec 10
Third quarter 2024 earnings released: EPS: US$0.71 (vs US$0.33 loss in 3Q 2023) Nov 09
Rigel Pharmaceuticals, Inc. Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition Nov 05
Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML Sep 05
New major risk - Share price stability Aug 13 See more updates
Rigel Pharmaceuticals, Inc. Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition Dec 10
Third quarter 2024 earnings released: EPS: US$0.71 (vs US$0.33 loss in 3Q 2023) Nov 09
Rigel Pharmaceuticals, Inc. Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition Nov 05
Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 31
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML Sep 05
New major risk - Share price stability Aug 13
Insufficient new directors Aug 09
Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application Jun 25
Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress Jun 15
Insufficient new directors Jun 02
First quarter 2024 earnings released: US$0.047 loss per share (vs US$0.078 loss in 1Q 2023) May 08
Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024 May 01
Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024 Apr 11
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer Mar 12
Forecast breakeven date moved forward to 2025 Mar 07
Full year 2023 earnings released: US$0.14 loss per share (vs US$0.34 loss in FY 2022) Mar 07
Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024 Feb 28
President recently sold €56k worth of stock Feb 08
No longer forecast to breakeven Dec 21
Forecast to breakeven in 2025 Dec 03
Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Nov 30
New major risk - Share price stability Nov 28
Forecast to breakeven in 2025 Nov 13
Third quarter 2023 earnings released: US$0.033 loss per share (vs US$0.11 loss in 3Q 2022) Nov 08
Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition Nov 03
Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial Oct 12
New minor risk - Profitability Aug 03
Forecast to breakeven in 2025 Aug 02
Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 26
Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML Jun 08
Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics Jun 07
Full year 2022 earnings released: US$0.34 loss per share (vs US$0.10 loss in FY 2021) May 03
Forecast to breakeven in 2025 May 03
Full year 2022 earnings released: US$0.34 loss per share (vs US$0.10 loss in FY 2021) Mar 08
Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023 Feb 04
Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances Feb 03
National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia Jan 19
Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022 Jan 10
Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation Dec 24
Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes Dec 16
Now 21% undervalued after recent price drop Dec 10
Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation Dec 02
Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Nov 30
Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology Nov 11
Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2021) Nov 05
Now 21% undervalued after recent price drop Nov 04
Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Focus Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized Covid-19 Patients Nov 02
Rigel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Rigel Pharmaceuticals, Inc. Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback Oct 11
Second quarter 2022 earnings released: US$0.078 loss per share (vs US$0.081 loss in 2Q 2021) Aug 03
Rigel Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 02, 2022 Jul 28
President recently bought €646k worth of stock Jun 15
Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Forward Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia Jun 09
No longer forecast to breakeven May 06
First quarter 2022 earnings released: US$0.16 loss per share (vs US$0.23 profit in 1Q 2021) May 05
Rigel Pharmaceuticals, Inc., Annual General Meeting, May 19, 2022 Apr 06 Rigel Pharmaceuticals, Inc. Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology Mar 10
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 03
Rigel Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 24 Rigel Pharmaceuticals, Inc. Provides the Status of the Phase 3 Study in Covid-19
No longer forecast to breakeven Nov 24
Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.084 loss in 3Q 2020) Nov 03
Forecast to breakeven in 2023 Sep 23
Rigel Pharmaceuticals, Inc. Announces Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases Sep 02
Second quarter 2021 earnings released: US$0.081 loss per share (vs US$0.10 loss in 2Q 2020) Aug 05
First quarter 2021 earnings released: EPS US$0.23 (vs US$0.13 in 1Q 2020) May 06
Rigel Announces Completion of Patient Enrollment for Nih/Nhlbi-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized Covid-19 Patients Mar 12
Full year 2020 earnings released: US$0.18 loss per share (vs US$0.40 loss in FY 2019) Mar 04
Revenue beats expectations Mar 04
Rigel Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 02, 2021 Feb 24
Eli Lilly and Company and Rigel Pharmaceuticals, Inc. Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases Feb 19
New 90-day high: €3.14 Feb 03
Rigel Pharmaceuticals, Inc. Awards $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in Covid-19 Patients Jan 31
New 90-day high: €3.06 Jan 15
New 90-day high: €2.54 Dec 10
Rigel Announces Two Posters Highlighting Tavalisse At the 62Nd Ash Annual Meeting & Exposition Dec 06
Rigel Pharmaceuticals, Inc. and Medison Pharma Announces Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia Nov 24
Rigel Pharmaceuticals, Inc. Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia Nov 18
Third quarter 2020 earnings released: US$0.084 loss per share Nov 07
Revenue beats expectations Nov 07
New 90-day high: €2.26 Nov 05
Rigel Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
Rigel Pharmaceuticals, Inc. Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova Oct 11
Rigel Pharmaceuticals, Inc. Announces Resignation of Nelson D. Cabatuan as Vice President, Finance and Principal Accounting Officer, Effective on October 16, 2020 Oct 10
Rigel Pharmaceuticals, Inc. Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova Sep 18
First half earnings released Aug 06 Shareholder Returns RI2 DE Biotechs DE Market 7D -10.7% 6.5% 1.3% 1Y 24.8% -1.9% 9.0%
See full shareholder returns
Return vs Market: RI2 exceeded the German Market which returned 10.1% over the past year.
Price Volatility Is RI2's price volatile compared to industry and market? RI2 volatility RI2 Average Weekly Movement 14.4% Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: RI2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RI2's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company.
Show more Rigel Pharmaceuticals, Inc. Fundamentals Summary How do Rigel Pharmaceuticals's earnings and revenue compare to its market cap? RI2 fundamental statistics Market cap €279.40m Earnings (TTM ) €3.79m Revenue (TTM ) €153.61m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) RI2 income statement (TTM ) Revenue US$157.37m Cost of Revenue US$37.58m Gross Profit US$119.79m Other Expenses US$115.91m Earnings US$3.88m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 0.22 Gross Margin 76.12% Net Profit Margin 2.47% Debt/Equity Ratio -681.5%
How did RI2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 09:09 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Rigel Pharmaceuticals, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Birchenough Barclays Clarence Powell BMO Capital Markets Equity Research James Birchenough BMO Capital Markets Equity Research
Show 24 more analysts 
